Employees: 1,354
Size Jiangsu Jibeier Pharmaceutical (688566.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $727M, the 2810th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.32 on 18 Nov 2026.
Performance Over six months the shares fell 9.4%, against -7.0% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +0.7%); the operating margin is 26.2% (peer median 9.6%).
Valuation It trades at 11.2× forward earnings against a peer median of 16.1× (3rd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.7 points above its cost of capital (8.3% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.04B | CN¥954M | CN¥886M | CN¥853M | CN¥648M |
| Revenue growth | — | +8% | +4% | +32% | — |
| Gross profit | CN¥937M | CN¥842M | CN¥787M | CN¥754M | CN¥567M |
| EBITDA | n/a | CN¥266M | CN¥300M | CN¥243M | CN¥170M |
| Net income | CN¥241M | CN¥262M | CN¥219M | CN¥219M | CN¥155M |
| Free cash flow | CN¥223M | CN¥137M | CN¥46.3M | -CN¥193M | -CN¥130M |
| Capital expenditure | CN¥84.0M | CN¥115M | CN¥175M | CN¥357M | CN¥293M |
| Total debt | CN¥7.05M | CN¥18.7M | CN¥20.8M | CN¥9.91M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688566.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -1.9% | 6th lowest of 21 |
| 6-month return | -9.4% | -7.0% | 10th lowest of 21 |
| Distance from 52-week high | -27.6% | -34.0% | 7th highest of 21 |
| Revenue growth (TTM) | +8.2% | +0.7% | 6th highest of 19 |
| Operating margin | 26.2% | 9.6% | 2nd highest of 19 |
| Forward P/E | 11.2× | 16.1× | 3rd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | 5.9% | -0.7% | 5th most demanding of 13 |
| Growth delivered (Del g) | +11.3% | +0.2% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -5.4 pp | -0.8 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +4.7 pp | +0.2 pp | 5th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 16.7× | -2.0% | +26.1% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | n/a | -2.1% | 0.0% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | n/a | 9.4% | -1.4% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | n/a | 13.5% | -0.2% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | n/a | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |